Table 1.
Characteristics of tocilizumab and tumor necrosis factor inhibitors
| Tocilizumab | Infliximab | Adalimumab | Golimumab | Certolizumab pegol | Etanercept | |
|---|---|---|---|---|---|---|
| Target molecule | IL-6R | TNF-α | TNF-α | TNF-α | TNF-α | TNF-α Lymphotoxin |
| Structure | Humanized Ig | Chimeric Ig | Fully human Ig | Fully human Ig | Humanized Fab-pegol | P75TNFR-Fc |
| Injection route | IV, SC | IV | SC | SC | SC | SC |
| Activity | ||||||
| ADCC | + | + | + | + | − | + |
| CDCC | + | + | + | + | − | ± |
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CDCC, complement-dependent cellular cytotoxicity; Ig, immunoglobulin; IL-6R, interleukin-6 receptor; IV, intravenously; SC, subcutaneously; TNF-α, tumor necrosis factor-α; TNFR, TNF receptor.